WO2001093845A3 - Carboxyalkylether-acat inhibitor combinations - Google Patents

Carboxyalkylether-acat inhibitor combinations Download PDF

Info

Publication number
WO2001093845A3
WO2001093845A3 PCT/US2001/014804 US0114804W WO0193845A3 WO 2001093845 A3 WO2001093845 A3 WO 2001093845A3 US 0114804 W US0114804 W US 0114804W WO 0193845 A3 WO0193845 A3 WO 0193845A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxyalkylether
acat inhibitor
formula
inhibitor combinations
acat
Prior art date
Application number
PCT/US2001/014804
Other languages
French (fr)
Other versions
WO2001093845A2 (en
Inventor
Bruce Jeffrey Auerbach
Donna Lee Zobel
Original Assignee
Warner Lambert Co
Bruce Jeffrey Auerbach
Donna Lee Zobel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Bruce Jeffrey Auerbach, Donna Lee Zobel filed Critical Warner Lambert Co
Priority to JP2002501418A priority Critical patent/JP2003535125A/en
Priority to MXPA02010762A priority patent/MXPA02010762A/en
Priority to BR0111428-0A priority patent/BR0111428A/en
Priority to US10/182,747 priority patent/US20040072903A1/en
Priority to CA002413906A priority patent/CA2413906A1/en
Priority to AU2001263003A priority patent/AU2001263003A1/en
Priority to EP01937250A priority patent/EP1292363A2/en
Publication of WO2001093845A2 publication Critical patent/WO2001093845A2/en
Publication of WO2001093845A3 publication Critical patent/WO2001093845A3/en
Priority to US11/157,106 priority patent/US20050234124A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and LDL and elevates HDL, and an ACAT inhibitor which improves dyslipidemias in mammals, said composition being useful for treating dyslipidemia and ischemic syndromes, and for preventing or delaying the onset of heart attacks. The carboxyalkylethers have the formula (I) wherein Y1 and Y2 include COOH, R1, R2, R3, and R4 can be alkyl, and n and m are integers from 2 to 9; and the ACAT inhibitors have the formula (IV) where R is hydrogen, X is O, R1 and R2 are substituted phenyl, and Y is alkylene.
PCT/US2001/014804 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations WO2001093845A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2002501418A JP2003535125A (en) 2000-06-07 2001-05-08 Carboxyalkyl ether-ACAT inhibitor combination
MXPA02010762A MXPA02010762A (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations.
BR0111428-0A BR0111428A (en) 2000-06-07 2001-05-08 Combinations of carboxyalkyl ether and acat inhibitor
US10/182,747 US20040072903A1 (en) 2001-05-08 2001-05-08 Carboxyalkylether-acat inhibitors combinations
CA002413906A CA2413906A1 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations
AU2001263003A AU2001263003A1 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations
EP01937250A EP1292363A2 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations
US11/157,106 US20050234124A1 (en) 2001-05-08 2005-06-20 Carboxyalkylether-ACAT inhibitor combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21005600P 2000-06-07 2000-06-07
US60/210,056 2000-06-07

Publications (2)

Publication Number Publication Date
WO2001093845A2 WO2001093845A2 (en) 2001-12-13
WO2001093845A3 true WO2001093845A3 (en) 2002-10-10

Family

ID=22781424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014804 WO2001093845A2 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations

Country Status (14)

Country Link
EP (1) EP1292363A2 (en)
JP (1) JP2003535125A (en)
AR (1) AR034255A1 (en)
AU (1) AU2001263003A1 (en)
BR (1) BR0111428A (en)
CA (1) CA2413906A1 (en)
GT (1) GT200100106A (en)
MX (1) MXPA02010762A (en)
PA (1) PA8518601A1 (en)
PE (1) PE20020265A1 (en)
SV (1) SV2002000466A (en)
TN (1) TNSN01085A1 (en)
UY (1) UY26752A1 (en)
WO (1) WO2001093845A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387236B2 (en) 2001-10-09 2008-06-17 Delaware Capital Formation, Inc. Dispensing of currency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease

Also Published As

Publication number Publication date
JP2003535125A (en) 2003-11-25
GT200100106A (en) 2002-05-20
BR0111428A (en) 2003-06-10
TNSN01085A1 (en) 2005-11-10
AR034255A1 (en) 2004-02-18
EP1292363A2 (en) 2003-03-19
PA8518601A1 (en) 2002-07-30
AU2001263003A1 (en) 2001-12-17
CA2413906A1 (en) 2001-12-13
WO2001093845A2 (en) 2001-12-13
SV2002000466A (en) 2002-04-03
UY26752A1 (en) 2001-07-31
PE20020265A1 (en) 2002-04-19
MXPA02010762A (en) 2003-03-10

Similar Documents

Publication Publication Date Title
ATE267172T1 (en) 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROCINOLINE AS A CETP INHIBITOR
BG105428A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
BG105429A (en) 4-amino-substituted-2-substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
MXPA02012252A (en) HMG-CoA REDUCTASE INHIBITORS AND METHOD.
BR9904162A (en) 4-carboxyamino-2-methyl-1,2,3,4-ringed tetrahydroquinolines
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
EP1180514A4 (en) Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
WO1999005096A3 (en) Urokinase inhibitors
AU2001274220A1 (en) Serine protease inhibitors
WO2002046314A3 (en) Perylene pigment compositions
FI935777A0 (en) Inhibitor Foer HIV-Proteas can be used to treat AIDS
ATE350443T1 (en) BIOCIDAL CLEANING AGENT
DE69833797D1 (en) SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS
WO2001093845A3 (en) Carboxyalkylether-acat inhibitor combinations
SI1377574T1 (en)
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
EP1114820A4 (en) Thiazolylcinnamonitriles and pest controlling agents
EP1283208A4 (en) Novel benzofuran derivatives
DE60124519D1 (en) TRIYDROXYBENZES FOR PREVENTING THE CORROSION OF TITANIUM
WO2002000624A3 (en) Methods and compounds for inhibiting mrp1
DOP2001000184A (en) ACAT CARBOXIALQUILETER-INHIBITOR COMBINATIONS
FI935867A (en) TETRAHYDROBENSAZEPINDERIVAT SOM INHIBITERAR LIPOXIGENAS
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor
BR0115241B1 (en) assembly comprising a product and a packaging sheet and a packaging sheet manufacturing process.
FI935552A0 (en) N-hydroxyureas, vilkai inhiberar lipoxygenas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10182747

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010762

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001937250

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2413906

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 501418

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001937250

Country of ref document: EP